Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)

A framework to rank genomic alterations as targets for cancer precision medicine

A collaborative project initiated by the ESMO Translational Research and Precision Medicine Working Group  provides a systematic framework to rank molecular targets based on evidence available supporting their value as clinical targets.

Implementation of a harmonised vocabulary would help clinicians to prioritise cancer genomic abnormalities when interpreting genomic reports and facilitate communication between academia, pharmaceutical industry, healthcare professionals and patients.

The ESCAT is published in 2018 in the Annals of Oncology and accompanied with a press release.

To enquire or ask questions about the ESMO Scale for Clinical Actionability of molecular Targets, please send an email to education@esmo.org 

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings